The week in industry: Canada approves its first ever RNAi therapeutic
This week: Orphan Status granted for Muscular Atrophy treatment, The AMR Centre and Shionogi join forces to further develop antiviral treatment and Takeda extends option to develop Humabody therapies.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>